Floatz logo

shc014748m

Marginal Zone Lymphoma(MZL)

Nanjing Sanhome Pharmaceutical, Co., Ltd.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

106 Active assets in the Marginal Zone Lymphoma(MZL) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

shc014748m is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
51 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →